Carl L Gordon's Net Worth

$553 Million

Estimate Recalculated Apr 23, 2024 03:08PM EST

Who is Carl L Gordon?

Carl L Gordon has an estimated net worth of $553 Million. This is based on reported shares across multiple companies, which include Adicet Bio, Inc., ArriVent Biopharma, Inc., COMPLETE GENOMICS INC, Turning Point Therapeutics, Inc., AMARIN CORP PLC\UK, Keros Therapeutics, Inc., Intellia Therapeutics, Inc., Theseus Pharmaceuticals, Inc., Alector, Inc., Kinnate Biopharma Inc., SpringWorks Therapeutics, Inc., ACADIA PHARMACEUTICALS INC, Pacira Pharmaceuticals, Inc., BIOCRYST PHARMACEUTICALS INC, ARMO BioSciences, Inc., Prevail Therapeutics Inc., Gemini Therapeutics, Inc. /DE, BiomX Inc., SELECTA BIOSCIENCES INC, Terns Pharmaceuticals, Inc., Oric Pharmaceuticals, Inc., Compass Therapeutics, Inc., Arsanis, Inc., and ACCELERON PHARMA INC.

SEC CIK

Carl L Gordon's CIK is 0001282930

Past Insider Trading and Trends

2023 was Carl L Gordon's most active year for acquiring shares with 36 total transactions. Carl L Gordon's most active month to acquire stocks was the month of January. 2011 was Carl L Gordon's most active year for disposing of shares, totalling 48 transactions. Carl L Gordon's most active month to dispose stocks was the month of February. 2019 saw Carl L Gordon paying a total of $29,302,284.00 for 26,549,042 shares, this is the most they've acquired in one year. In 2018 Carl L Gordon cashed out on 8,255,806 shares for a total of $206,125,690.00, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Adicet Bio, Inc. (ACET) Snapshot price: $3.25

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+47.01%
3.13M
$2.40
$7,500,000.00
9.77M
Jan 25
Form 4
—
0
—
—
0
Aug 14
Form 4
+12.10%
875K
$2.09
$1,828,750.00
8.11M
Jun 27
Form 4
∞
5.9K
—
—
5.9K
Jun 1
Form 4
—
0
—
—
0
Jun 2
Form 4
+765.30%
214.28K
$14.00
$2,999,990.00
242.28K
Dec 10
Form 4
—
0
—
—
0
Apr 30
Form 4
+10.25%
524.35K
$13.00
$6,816,537.00
5.64M
Feb 12
Form 4
∞
6.02M
—
—
6.02M
Sep 15 - Sep 17
Form 3
—
0
—
—
0
No matching records found

ArriVent Biopharma, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+143.25%
3.03M
$18.00
$3,999,996.00
5.14M
Jan 30
Form 3
—
0
—
—
0
No matching records found

COMPLETE GENOMICS INC No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Nov 30
Form 3
—
0
—
—
0
No matching records found

Turning Point Therapeutics, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Jun 15
Form 4
∞
2.03M
$18.00
—
2.03M
Apr 22
Form 3
—
0
—
—
0
No matching records found

AMARIN CORP PLC\UK (AMRN) Snapshot price: $1.195

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-28.03%
-233.70K
$14.43
-$3,372,992.10
600K
Scheduled
Sep 4
Form 4
-30.53%
-366.30K
$14.61
-$5,350,690.62
833.7K
Scheduled
Jul 27
Form 4
—
0
—
—
0
Jul 10
Form 4
-33.96%
-617.10K
$14.46
-$7,986,701.24
1.2M
Jun 19
Form 4
-3.50%
-132.90K
$16.16
-$2,137,270.00
3.67M
Apr 29 - May 2
Form 4/A
-22.86%
-800.00K
$15.79
-$12,632,000.00
2.7M
Apr 20
Form 4
-14.56%
-750.00K
$16.54
-$12,500,000.00
4.4M
Apr 21
Form 4
-20.85%
-3.80M
$15.64
-$58,181,898.51
14.43M
Scheduled
Apr 18 - Apr 20
Form 4
-0.87%
-173.00K
$7.44
-$1,281,828.00
19.74M
Mar 24 - Mar 28
Form 4
-1.14%
-77.00K
$7.05
-$542,850.00
6.67M
Mar 21
Form 4
-1.09%
-225.00K
$7.33
-$1,654,750.00
20.43M
Mar 11 - Mar 15
Form 4
-0.36%
-75.00K
$7.69
-$573,980.00
21.02M
Mar 3 - Mar 7
Form 4
-1.13%
-245.00K
$7.67
-$1,884,400.00
21.39M
Feb 28 - Mar 2
Form 3
—
0
—
—
0
No matching records found